Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Al‐Horani, Daniel Afosah (2018)
Recent advances in the discovery and development of factor XI/XIa inhibitorsMedicinal Research Reviews, 38
Coronavirus disease 2019 ( COVID - 19 ) : people with certain medical conditions
E. Dong, H. Du, L. Gardner (2020)
An interactive web-based dashboard to track COVID-19 in real timeThe Lancet. Infectious Diseases, 20
Young-A. Heo (2018)
Andexanet Alfa: First Global ApprovalDrugs, 78
A. Shih, M. Crowther (2016)
Reversal of direct oral anticoagulants: a practical approach.Hematology. American Society of Hematology. Education Program, 2016 1
J. Schuettrumpf, J. Zou, Yi Zhang, A. Schlachterman, Yi-lin Liu, Shyrie Edmonson, W. Xiao, V. Arruda (2006)
The inhibitory effects of anticoagulation on in vivo gene transfer by adeno-associated viral or adenoviral vectors.Molecular therapy : the journal of the American Society of Gene Therapy, 13 1
Jan Vojáček (2017)
Should We Replace the Terms Intrinsic and Extrinsic Coagulation Pathways With Tissue Factor Pathway?Clinical and Applied Thrombosis/Hemostasis, 23
R. José, A. Manuel (2020)
COVID-19 cytokine storm: the interplay between inflammation and coagulationThe Lancet. Respiratory Medicine
A. Fb, F. Sariali̇oğlu (2020)
The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?Medical Hypotheses, 142
E. C. M. van Gorp, C. Suharti, H. ten Cate, W. Dolmans, J. W. M. van der Meer, J. W. ten Cate, D. Brandjes (1999)
Review: infectious diseases and coagulation disorders.The Journal of infectious diseases, 180 1
T. Oxley, J. Mocco, S. Majidi, C. Kellner, H. Shoirah, I. Singh, R. Leacy, T. Shigematsu, T. Ladner, K. Yaeger, M. Skliut, J. Weinberger, N. Dangayach, J. Bederson, S. Tuhrim, J. Fifi (2020)
Large-Vessel Stroke as a Presenting Feature of Covid-19 in the YoungThe New England Journal of Medicine
S. Deitelzweig, Caroline Farmer, Xuemei Luo, Xiaoyan Li, Lien Vo, Jack Mardekian, K. Fahrbach, A. Ashaye (2018)
Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysisCurrent Medical Research and Opinion, 34
C. Esmon (2005)
The interactions between inflammation and coagulationBritish Journal of Haematology, 131
K. Nogami, Qian Zhou, H. Wakabayashi, P. Fay (2005)
Thrombin-catalyzed activation of factor VIII with His substituted for Arg372 at the P1 site.Blood, 105 11
Jiaofeng Huang, Aiguo Cheng, Rahul Kumar, Yingying Fang, Gongping Chen, Yueyong Zhu, Su Lin (2020)
Hypoalbuminemia predicts the outcome of COVID‐19 independent of age and co‐morbidityJournal of Medical Virology, 92
W. Ruf (2014)
FXa takes center stage in vascular inflammation.Blood, 123 11
N. Tang, Huan Bai, Xing Chen, Jiale Gong, Dengju Li, Ziyong Sun (2020)
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathyJournal of Thrombosis and Haemostasis, 18
Emiko Shinozawa, Masaharu Nakayama, Y. Imura (2018)
TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1Frontiers in Pharmacology, 9
A. Bukowska, Ines Zacharias, S. Weinert, K. Skopp, C. Hartmann, C. Huth, A. Goette (2013)
Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue.European journal of pharmacology, 718 1-3
P. Zuo, Zhi Zuo, Xin Wang, Long Chen, Yueyue Zheng, G. Ma, Qianxing Zhou (2015)
Factor Xa induces pro-inflammatory cytokine expression in RAW 264.7 macrophages via protease-activated receptor-2 activation.American journal of translational research, 7 11
E. Hellenbart, K. Faulkenberg, Shannon Finks (2017)
Evaluation of bleeding in patients receiving direct oral anticoagulantsVascular Health and Risk Management, 13
N. Senden, Trudi Jeunhomme, J. Heemskerk, R. Wagenvoord, C. Veer, H. Hemker, W. Buurman (1998)
Factor Xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells.Journal of immunology, 161 8
B. Mohammed, A. Matafonov, I. Ivanov, Mao-fu Sun, Qiufang Cheng, S. Dickeson, Chan Li, David Sun, I. Verhamme, J. Emsley, D. Gailani (2018)
An update on factor XI structure and function.Thrombosis research, 161
M. Cattaneo, Elena Bertinato, S. Birocchi, Carolina Brizio, Daniele Malavolta, Marco Manzoni, G. Muscarella, M. Orlandi (2020)
Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?Thrombosis and Haemostasis, 120
R. Groot, S. Baker, R. Baric, C. Brown, C. Drosten, L. Enjuanes, R. Fouchier, M. Galiano, A. Gorbalenya, Z. Memish, S. Perlman, L. Poon, E. Snijder, G. Stephens, P. Woo, A. Zaki, M. Zambon, J. Ziebuhr (2013)
Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study GroupJournal of Virology, 87
M. Ranucci, A. Ballotta, U. Dedda, Ekaterina Bayshnikova, Marco Poli, M. Resta, M. Falco, G. Albano, L. Menicanti (2020)
The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndromeJournal of Thrombosis and Haemostasis, 18
H. Bounameaux, bullet Camm (2014)
Edoxaban: An Update on the New Oral Direct Factor Xa InhibitorDrugs, 74
Mahesh Madhavan, B. Bikdeli, Aakriti Gupta, D. Jiménez, John Burton, Caroline Nigoghossian, Taylor Chuich, S. Nouri, Isaac Dreyfus, E. Driggin, S. Sethi, K. Sehgal, S. Chatterjee, W. Ageno, M. Madjid, Yutao Guo, Liang Tang, Yu Hu, L. Bertoletti, Jay Giri, M. Cushman, I. Quéré, E. Dimakakos, C. Gibson, G. Lippi, E. Favaloro, J. Fareed, Alfonso Tafur, D. Francese, J. Batra, A. Falanga, K. Clerkin, N. Uriel, A. Kirtane, C. McLintock, Beverley Hunt, A. Spyropoulos, Geoffrey Barnes, John Eikelboom, I. Weinberg, S. Schulman, M. Carrier, G. Piazza, Joshua Beckman, Martin Leon, G. Stone, S. Rosenkranz, S. Goldhaber, S. Parikh, M. Monreal, H. Krumholz, Stavros Konstantinides, J. Weitz, G. Lip (2020)
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future ResearchThrombosis and Haemostasis, 120
J. Shang, Yushun Wan, C. Luo, G. Ye, Q. Geng, Ashley Auerbach, Fang Li (2020)
Cell entry mechanisms of SARS-CoV-2Proceedings of the National Academy of Sciences of the United States of America, 117
S. Belouzard, Victor Chu, G. Whittaker (2009)
Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sitesProceedings of the National Academy of Sciences, 106
J. Ansell (2007)
Factor Xa or thrombin: is factor Xa a better target?Journal of Thrombosis and Haemostasis, 5
Gayatri Kanade, Kunal Pingale, Yogesh Karpe (2018)
Activities of Thrombin and Factor Xa Are Essential for Replication of Hepatitis E Virus and Are Possibly Implicated in ORF1 Polyprotein ProcessingJournal of Virology, 92
G. Cirino, C. Cicala, M. Bucci, L. Sorrentino, G. Ambrosini, G. DeDominicis, D. Altieri (1997)
Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo.The Journal of clinical investigation, 99 10
K. Duchin, A. Duggal, G. Atiee, M. Kidokoro, Tadanobu Takatani, N. Shipitofsky, Ling He, George Zhang, T. Kakkar (2017)
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy AdultsClinical Pharmacokinetics, 57
P. Merlini, D. Ardissino, K. Bauer, L. Oltrona, A. Pezzano, B. Bottasso, R. Rosenberg, P. Mannucci (1997)
Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes.Arteriosclerosis, thrombosis, and vascular biology, 17 7
Yan Deng, Wei Liu, Kui Liu, Yuan-yuan Fang, J. Shang, Ling Zhou, Ke Wang, Fan Leng, Shuang Wei, Lei Chen, Hui-guo Liu (2020)
Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective studyChinese Medical Journal, 133
U. Lindahl, Jin-ping Li (2020)
Heparin – An old drug with multiple potential targets in Covid‐19 therapyJournal of Thrombosis and Haemostasis, 18
(The US Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): people with certain medical conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html. Accessed 23 June 2020.)
The US Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): people with certain medical conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html. Accessed 23 June 2020.The US Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): people with certain medical conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html. Accessed 23 June 2020., The US Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): people with certain medical conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html. Accessed 23 June 2020.
FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients
G. Tomaselli, K. Mahaffey, A. Cuker, P. Dobesh, J. Doherty, J. Eikelboom, R. Florido, W. Hucker, R. Mehran, S. Messé, C. Pollack, Fatima Rodriguez, R. Sarode, D. Siegal, B. Wiggins (2017)
2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.Journal of the American College of Cardiology, 70 24
P. Kirchhof, M. Ezekowitz, Y. Purmah, Sonja Schiffer, I. Meng, A. Camm, S. Hohnloser, A. Schulz, M. Wosnitza, R. Cappato (2020)
Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT TrialTH Open: Companion Journal to Thrombosis and Haemostasis, 4
Scott Garland, Christina DeRemer, Steven Smith, J. Gums (2018)
Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized PatientsAnnals of Pharmacotherapy, 52
J. Thachil (2020)
The versatile heparin in COVID‐19Journal of Thrombosis and Haemostasis, 18
Chao-min Wu, Xiaoyan Chen, Y. Cai, Jia’an Xia, Xiaoping Zhou, Shan Xu, Hanping Huang, Li Zhang, Xia Zhou, C. Du, Yuye Zhang, Juan Song, Sijiao Wang, Yencheng Chao, Zeyong Yang, Jie Xu, Xin Zhou, Dechang Chen, W. Xiong, Lei Xu, F. Zhou, Jinjun Jiang, C. Bai, Junhua Zheng, Yuanlin Song (2020)
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaThe Journal of Emergency Medicine, 58
Fakiha Siddiqui, D. Hoppensteadt, W. Jeske, O. Iqbal, A. Tafur, J. Fareed (2019)
Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic SpectrumClinical and Applied Thrombosis/Hemostasis, 25
B. Dahlbäck (2017)
Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein SJournal of Thrombosis and Haemostasis, 15
N. Tang, Dengju Li, Xiong Wang, Ziyong Sun (2020)
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJournal of Thrombosis and Haemostasis, 18
Safieh Ebrahimi, S. Rezaei, Parvaneh Seiri, Mikhail Ryzhikov, S. Hashemy, S. Hassanian (2017)
Factor Xa Signaling Contributes to the Pathogenesis of Inflammatory DiseasesJournal of Cellular Physiology, 232
H. Versteeg, J. Heemskerk, M. Levi, P. Reitsma (2013)
New fundamentals in hemostasis.Physiological reviews, 93 1
Jason Kim, Jenny Zhang, Yoonjeong Cha, S. Kolitz, J. Funt, Renan Chong, S. Barrett, R. Kusko, B. Zeskind, H. Kaufman (2020)
Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)Journal of Translational Medicine, 18
E. Davie, K. Fujikawa, W. Kisiel (1991)
The coagulation cascade: initiation, maintenance, and regulation.Biochemistry, 30 43
N. Mackman, W. Bergmeier, G. Stouffer, J. Weitz (2020)
Therapeutic strategies for thrombosis: new targets and approachesNature Reviews Drug Discovery, 19
W. Byon, S. Garonzik, R. Boyd, C. Frost (2019)
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic ReviewClinical Pharmacokinetics, 58
Yuji Oe, S. Hayashi, Tomofumi Fushima, Emiko Sato, K. Kisu, Hiroshi Sato, S. Ito, N. Takahashi (2016)
Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic NephropathyArteriosclerosis, Thrombosis, and Vascular Biology, 36
L. Du, R. Kao, Yusen Zhou, Yuxian He, Guangyu Zhao, C. Wong, Shibo Jiang, K. Yuen, D. Jin, B. Zheng (2007)
Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivityBiochemical and Biophysical Research Communications, 359
A. Barrett, N. Rawlings, J. Woessner (1998)
Handbook of proteolytic enzymes
R. Walker, S. Krishnaswamy (1994)
The activation of prothrombin by the prothrombinase complex. The contribution of the substrate-membrane interaction to catalysis.The Journal of biological chemistry, 269 44
D. Giannis, I. Ziogas, Panagiota Gianni (2020)
Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the pastJournal of Clinical Virology, 127
N. Singhania, S. Bansal, D. Nimmatoori, A. Ejaz, P. McCullough, G. Singhania (2020)
Current Overview on Hypercoagulability in COVID-19American Journal of Cardiovascular Drugs, 20
D. Cucinotta, M. Vanelli (2020)
WHO Declares COVID-19 a PandemicActa Bio Medica : Atenei Parmensis, 91
E. Pryzdial, M. Sutherland, Bryan Lin, M. Horwitz (2020)
Antiviral anticoagulationResearch and Practice in Thrombosis and Haemostasis, 4
P. Demelo-Rodríguez, E. Cervilla-Muñoz, L. Ordieres-Ortega, A. Parra-Virto, M. Toledano-Macías, N. Toledo-Samaniego, Alejandra García-García, Irene García-Fernández-Bravo, Z. Ji, J. de-Miguel-Diez, L. Álvarez-Sala-Walther, J. del-Toro-Cervera, F. Galeano-Valle, F. Galeano-Valle (2020)
Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levelsThrombosis Research, 192
Stephanie Smith, R. Travers, J. Morrissey (2015)
How it all starts: Initiation of the clotting cascadeCritical Reviews in Biochemistry and Molecular Biology, 50
S. Antoniak, N. Mackman (2014)
Multiple roles of the coagulation protease cascade during virus infection.Blood, 123 17
C. Yeh, J. Fredenburgh, J. Weitz (2012)
Oral Direct Factor Xa InhibitorsCirculation Research, 111
Hiromasa Katoh, T. Nozue, I. Michishita (2017)
Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillationHeart and Vessels, 32
S. Schulman (1964)
Coagulation CascadeBritish Medical Journal, 1
T. Iba, J. Levy, M. Levi, J. Thachil (2020)
Coagulopathy in COVID‐19Journal of Thrombosis and Haemostasis, 18
(2008)
Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activationAm J Pathol, 172
W. Mueck, B. Eriksson, K. Bauer, L. Borris, O. Dahl, W. Fisher, M. Gent, S. Haas, M. Huisman, A. Kakkar, P. Kälebo, L. Kwong, F. Misselwitz, A. Turpie (2008)
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic SurgeryClinical Pharmacokinetics, 47
(2020)
Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, ChinaJAMA Intern Med, 180
Ronny Malz, A. Weithauser, C. Tschöpe, H. Schultheiss, U. Rauch (2014)
Inhibition of coagulation factor Xa improves myocardial function during CVB3-induced myocarditis.Cardiovascular therapeutics, 32 3
Christopher Barrett, H. Moore, M. Yaffe, E. Moore (2020)
ISTH interim guidance on recognition and management of coagulopathy in COVID‐19: A commentJournal of Thrombosis and Haemostasis, 18
K. Borensztajn, J. Stiekema, S. Nijmeijer, P. Reitsma, M. Peppelenbosch, C. Spek (2010)
Cardiovascular , Pulmonary and Renal Pathology Factor Xa Stimulates Proinflammatory and Profibrotic Responses in Fibroblasts via Protease-Activated Receptor-2 Activation
Taisheng Li, Hongzhou Lu, Wenhong Zhang (2020)
Clinical observation and management of COVID-19 patientsEmerging Microbes & Infections, 9
A. Minno, B. Frigerio, Gaia Spadarella, A. Ravani, D. Sansaro, M. Amato, J. Kitzmiller, M. Pepi, E. Tremoli, D. Baldassarre (2017)
Old and new oral anticoagulants: Food, herbal medicines and drug interactions.Blood reviews, 31 4
M. Sutherland, W. Ruf, E. Pryzdial (2009)
Factor Xa and Factor VIIa Utilize Herpes Simplex Virus-Associated Tissue Factor to Increase Infection through Cellular Protease Activated Receptor 2.Blood, 114
Florian Bompard, Hippolyte Monnier, Inès Saab, M. Tordjman, H. Abdoul, L. Fournier, O. Sanchez, C. Lorut, G. Chassagnon, M. Revel (2020)
Pulmonary embolism in patients with COVID-19 pneumoniaThe European Respiratory Journal, 56
K. Tellor, Naomi Barasch, Brian Lee (2018)
Clinical experience reversing factor Xa inhibitors with four-factor prothrombin complex concentrate in a community hospital.Blood transfusion = Trasfusione del sangue, 16 4
Stephanie Kustos, P. Fasinu (2019)
Direct-Acting Oral Anticoagulants and Their Reversal Agents—An UpdateMedicines, 6
D. White, S. MacDonald, T. Bull, M. Hayman, R. Monteverde-Robb, D. Sapsford, A. Lavinio, J. Varley, A. Johnston, M. Besser, W. Thomas (2020)
Heparin resistance in COVID-19 patients in the intensive care unitJournal of Thrombosis and Thrombolysis, 50
T. Nakase, J. Moroi, T. Ishikawa (2018)
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patientsClinical and Translational Medicine, 7
J. Thachil, N. Tang, S. Gando, A. Falanga, M. Levi, Cary Clark, T. Iba, M. Cattaneo (2020)
Type and dose of heparin in Covid‐19: ReplyJournal of Thrombosis and Haemostasis, 18
R. Al‐Horani, Srabani Kar (2020)
Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.European journal of medicinal chemistry, 200
I. Demidyuk, T. Gromova, S. Kostrov (2013)
Handbook of proteolytic enzymes, 3rd Edition
(US FDA. FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approved-betrixaban-bevyxxa-portola-prophylaxis-venous-thromboembolism-vte-adult-patients. Accessed 25 Aug 2020.)
US FDA. FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approved-betrixaban-bevyxxa-portola-prophylaxis-venous-thromboembolism-vte-adult-patients. Accessed 25 Aug 2020.US FDA. FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approved-betrixaban-bevyxxa-portola-prophylaxis-venous-thromboembolism-vte-adult-patients. Accessed 25 Aug 2020., US FDA. FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approved-betrixaban-bevyxxa-portola-prophylaxis-venous-thromboembolism-vte-adult-patients. Accessed 25 Aug 2020.
E. Epel, Alison Hartman, Laurie Jacobs, C. Leung, M. Cohn, L. Jensen, Laura Ishkanian, J. Wojcicki, Ashley Mason, R. Lustig, K. Stanhope, L. Schmidt (2020)
Association of a Workplace Sales Ban on Sugar-Sweetened Beverages With Employee Consumption of Sugar-Sweetened Beverages and Health.JAMA internal medicine
D. Green (2006)
Coagulation cascadeHemodialysis International, 10
V. Daubie, S. Cauwenberghs, N. Senden, R. Pochet, T. Lindhout, W. Buurman, J. Heemskerk (2006)
Factor Xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation.Biochimica et biophysica acta, 1763 8
M. Chan-Yeung, R. Xu (2003)
SARS: epidemiologyRespirology (Carlton, Vic.), 8
Human factor Xa (FXa) is a serine protease of the common coagulation pathway. FXa is known to activate prothrombin to thrombin, which eventually leads to the formation of cross-linked blood clots. While this process is important in maintaining hemostasis, excessive thrombin generation results in a host of thrombotic conditions. FXa has also been linked to inflammation via protease-activated receptors. Together, coagulopathy and inflammation have been implicated in the pathogenesis of viral infections, including the current coronavirus pandemic. Direct FXa inhibitors have been shown to possess anti-inflammatory and antiviral effects, in addition to their established anticoagulant activity. This review summarizes the pharmacological activities of direct FXa inhibitors, their pharmacokinetics, potential drug–drug interactions and adverse effects, and the details of clinical trials involving direct FXa inhibitors in coronavirus disease 2019 (COVID-19) patients.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Sep 12, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.